These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 30628956

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 7. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M, Fathy SA, Mehany NL, Hindy OW.
    Clin Chem Lab Med; 2007 Apr; 45(11):1498-503. PubMed ID: 17970704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
    Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E.
    Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA, Malaponte G, Pennisi P, Li Volti G, Trovato G, Mangiafico M, Bevelacqua Y, Mazza F, Fiore CE.
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [Abstract] [Full Text] [Related]

  • 16. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 17. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 18. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P, de la Higuera M, García DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jiménez F, Muñoz-Torres M.
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [Abstract] [Full Text] [Related]

  • 19. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease.
    Ugay L, Kochetkova E, Nevzorova V, Maistrovskaia Y.
    Chin Med J (Engl); 2016 Jul 20; 129(14):1696-703. PubMed ID: 27411457
    [Abstract] [Full Text] [Related]

  • 20. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
    Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Malaktari S, Athanasiou V, Tolis G.
    J Bone Miner Metab; 2007 Jul 20; 25(1):60-7. PubMed ID: 17187195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.